ArticleClinical kidney journal2024
Guidelines for the management of hypertension in CKD patients: where do we stand in 2024?
Article in Clinical kidney journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Effects of Aliskiren Monotherapy on Chronic Kidney Disease: A Systematic Review and Meta-Analysis of Blood Pressure and Urinary Protein Excretion Outcomes.Journal of clinical hypertension (Greenwich, Conn.) · 2026Pooled it
- [Recommendations for the Diagnosis and Treatment of Chronic Kidney Disease (CKD) by the Austrian Society of Nephrology].Wiener klinische Wochenschrift · 2025Guideline
- Genetic Testing for APOL1 in Adults With Hypertension: The GUARDD-US Randomized Clinical Trial.JAMA network open · 2026Trial
- Autophagy and Mitophagy in Hypertensive Chronic Kidney Disease: Evidence Grading, Cell-Type Divergence, and a Working Lysosomal Hypothesis.Life (Basel, Switzerland) · 2026Review
- Fruits, Vegetables, and Legumes: Harnessing the Gut-Kidney Axis in Hypertensive Chronic Kidney Disease.Foods (Basel, Switzerland) · 2026Review
- Renal Effects of Glucagon-like Peptide-1 Receptor Agonists in Diabetic Kidney Disease: A Narrative Review of Mechanisms and Clinical Evidence.Medicina (Kaunas, Lithuania) · 2026Review
- Systemic and proximal tubule specific knockout ofPhysiological genomics · 2026Article
- Mineralocorticoid receptor antagonists: Efficacy and safety in chronic kidney disease.Diabetes, obesity & metabolism · 2026Review
- Nocturnal hypertension in kidney transplant recipients: epidemiology, pathophysiology, prognostic significance, and management.Clinical kidney journal · 2026Review
- Hypertension-Induced Renal Injury: From Pathophysiology to Therapeutic Perspectives.Biomedicines · 2026Review
- Transdermal Clonidine for Hypertension: An Underutilized Ally in the Modern Era.High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension · 2026Review
- Clinical outcomes in MetALD compared with ALD in patients referred for liver transplant evaluation.Hepatology communications · 2026Article
- High-Phosphate-Induced Hypertension: The Pathogenic Role of Fibroblast Growth Factor 23 (FGF23) Signaling in Sympathetic Nervous System Activation.International journal of molecular sciences · 2026Review
- Heart Failure and Comorbidities (Chronic Kidney Disease, Diabetes, Obesity) Management: A Multidisciplinary Approach.Cardiorenal medicine · 2026Review
- Adherence to the European Society of Cardiology hypertension guidelines over 12 years of follow-up in the Irish population.Open heart · 2025Article
- Very low SBP targets and the boom-and-bust cycle of benefit and adverse kidney events.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2025Article
- Exosomes applications in kidney diseases.Molecular biology reports · 2025Review
- Beyond blood pressure: identifying factors associated with rapid kidney function decline in patients with CKD and coexisting COPD.International urology and nephrology · 2025Article
- Determinants of Health-Related Quality of Life in Patients with Chronic Kidney Disease: A Cross-Sectional Study.Healthcare (Basel, Switzerland) · 2025Article
- Critical Review of the Benefit from Early Pharmacological and Dietary Support for Patients with Moderate-to-Severe (Non-Terminal) Chronic Kidney Disease.Biomedicines · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Until recently, major bodies producing guidelines for the management of hypertension in patients with chronic kidney disease (CKD) disagreed in some key issues. In June 2023, the European Society of Hypertension (ESH) published the new 2023 ESH Guidelines for the management of arterial hypertension a document that was endorsed by the European Renal Association. Several novel recommendations relevant to the management of hypertension in patients with CKD appeared in these guidelines, which have been updated to reflect the latest evidence-based practices in managing hypertension in CKD patients. Most of these are in general agreement with the previous 2021 Kidney Disease: Improving Global Outcomes (KDIGO) guidelines-some reflect different emphasis on some topics (i.e. detailed algorithms on antihypertensive agent use) while others reflect evolution of important evidence in recent years. The aim of the present review is to summarize and comment on key points and main areas of focus in patients with CKD, as well as to compare and highlight the main differences with the 2021 KDIGO Guidelines for the management of blood pressure in CKD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.